Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Synthesis and evaluation of an orally available "Y"-shaped biaryl peroxisome proliferator-activated receptor δ agonist.

Kim DS, Lee J, Londhe AM, Kadayat TM, Joo J, Hwang H, Kim KH, Pae AN, Chin J, Cho SJ, Kang H.

Bioorg Med Chem. 2018 Jul 20. pii: S0968-0896(18)30903-9. doi: 10.1016/j.bmc.2018.06.044. [Epub ahead of print]

PMID:
30054191
2.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

PMID:
29630978
3.

Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.

Farag AK, Elkamhawy A, Londhe AM, Lee KT, Pae AN, Roh EJ.

Eur J Med Chem. 2017 Dec 1;141:657-675. doi: 10.1016/j.ejmech.2017.10.003. Epub 2017 Oct 4.

PMID:
29107425
4.

Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.

Kim T, Son WS, Morshed MN, Londhe AM, Jung SY, Park JH, Park WK, Lim SM, Park KD, Cho SJ, Jeong KS, Lee J, Pae AN.

Eur J Med Chem. 2017 Dec 1;141:240-256. doi: 10.1016/j.ejmech.2017.09.033. Epub 2017 Sep 21.

PMID:
29031071
5.

Discovery of non-peptidic small molecule inhibitors of cyclophilin D as neuroprotective agents in Aβ-induced mitochondrial dysfunction.

Park I, Londhe AM, Lim JW, Park BG, Jung SY, Lee JY, Lim SM, No KT, Lee J, Pae AN.

J Comput Aided Mol Des. 2017 Oct;31(10):929-941. doi: 10.1007/s10822-017-0067-9. Epub 2017 Sep 14.

PMID:
28913661
6.

In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level.

Park I, Hwang YJ, Kim T, Viswanath ANI, Londhe AM, Jung SY, Sim KM, Min SJ, Lee JE, Seong J, Kim YK, No KT, Ryu H, Pae AN.

J Comput Aided Mol Des. 2017 Oct;31(10):877-889. doi: 10.1007/s10822-017-0052-3. Epub 2017 Sep 6.

PMID:
28879500
7.

Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.

van de Velde H, Londhe A, Ataman O, Johns HL, Hill S, Landers E, Berlin JA.

Eur J Haematol. 2017 Mar;98(3):269-279. doi: 10.1111/ejh.12829. Epub 2016 Dec 17.

PMID:
27859769
9.

Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.

Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE, Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B.

Eur Urol. 2016 Sep;70(3):438-44. doi: 10.1016/j.eururo.2016.02.035. Epub 2016 Mar 7.

10.

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ.

Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.

11.

Feasibility and utility of applications of the common data model to multiple, disparate observational health databases.

Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, DeFalco FJ, Londhe A, Zhu V, Ryan PB.

J Am Med Inform Assoc. 2015 May;22(3):553-64. doi: 10.1093/jamia/ocu023. Epub 2015 Feb 10.

12.

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators.

Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2014 Nov;15(12):e528.

PMID:
25242048
13.

Evaluation of experimental coating to improve the zirconia-veneering ceramic bond strength.

Matani JD, Kheur M, Jambhekar SS, Bhargava P, Londhe A.

J Prosthodont. 2014 Dec;23(8):626-33. doi: 10.1111/jopr.12176. Epub 2014 Jun 27.

PMID:
24975232
14.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A.

Haematologica. 2014 Jun;99(6):1114-22. doi: 10.3324/haematol.2013.099341. Epub 2014 Apr 24.

15.

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2014 Feb;109(2):212-23. doi: 10.1038/ajg.2013.441. Epub 2014 Jan 7.

PMID:
24394749
16.

Expression, purification and crystallization of acetyl-CoA hydrolase from Neisseria meningitidis.

Khandokar YB, Londhe A, Patil S, Forwood JK.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Nov;69(Pt 11):1303-6. doi: 10.1107/S1744309113028042. Epub 2013 Oct 30.

17.

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee.

J Drugs Dermatol. 2012 Oct;11(10):1210-7.

PMID:
23134986
18.

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.

Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ.

Am J Gastroenterol. 2012 Sep;107(9):1409-22. doi: 10.1038/ajg.2012.218. Epub 2012 Aug 14.

19.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
20.

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.

Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ.

Cancer. 2011 Aug 15;117(16):3758-62. doi: 10.1002/cncr.25937. Epub 2011 Feb 15.

21.

Balloon atrial septostomy through internal jugular vein in a 45-day-old child with transposition of great arteries.

Padhi SS, Bakshi KD, Londhe AP.

Ann Pediatr Cardiol. 2010 Jan;3(1):77-9. doi: 10.4103/0974-2069.64363.

22.

Veno-venous shunt-assisted cavopulmonary anastomosis.

Kandakure PR, Dharmapuram AK, Kale SB, Babu V, Ramadoss N, Shastri R, Londhe A, Rao IM, Murthy KS.

Ann Pediatr Cardiol. 2010 Jan;3(1):8-11. doi: 10.4103/0974-2069.64361.

23.

Tricuspid valve repair with neopapillary muscle from right ventricular trabecula.

Kale SB, Rao IM, Londhe A, Saleh AA, Padhi SS, Murthy KS.

Ann Thorac Surg. 2010 Jul;90(1):320-2. doi: 10.1016/j.athoracsur.2009.08.059.

PMID:
20609817
24.

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease.

Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, Lulla A, Simpson RJ Jr.

Am J Cardiol. 1999 May 1;83(9):1303-7. Erratum in: Am J Cardiol 1999 Nov 1;84(9):1143.

PMID:
10235085
25.

Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction.

Simpson RJ Jr, Sueta CA, Boccuzzi SJ, Lulla A, Biggs D, Londhe A, Smith SC Jr.

Am J Cardiol. 1997 Oct 30;80(8B):53H-56H.

PMID:
9372999

Supplemental Content

Loading ...
Support Center